Has Matthew Trojan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $22,299 in general payments to Matthew Trojan, MD across 100 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Trojan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Trojan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Trojan, MD

Cardiovascular Disease · Springfield, ORNPI 1235150814

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,400 of the $22,299 with a category attached, or 60.1%. Boston Scientific accounts for 86.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $6,732 and has fallen 84.9% since, to $1,014 in 2025. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,299in general payments, 2019–2025

Across 100 payments — averaging $222.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$19K
Abbott$3K
Medtronic$122
Microvention, Inc.$30
Ablative Solutions, Inc.$18

$232,670in research payments, 2019–2025

Across 68 payments — averaging $3421.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$150K
Novartis$83K
Amgen$5

What the payments were for

Consulting fees$2,61812%
Speaking & faculty fees$13,40060%
Travel & lodging$4,80222%
Food & beverage$1,3926%
Education$870%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	87	$19,361
Abbott	8	$2,766
Medtronic(2 entities)	3	$122
Microvention, Inc.	1	$30
Ablative Solutions, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EMBLEM MRI S-ICD$5,000
GENERAL - THERAPIES$2,918
Optisure Defibrillation ICD Lead$2,618
EMBLEM$2,000
EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$2,000
CLINICAL TRIAL PRODUCT$1,587
INGEVITY$833
RESONATE$658

How this compares

$22,299 in reported general payments places this provider in the 90th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon →

Medicare billing

Part B allowed, 2024

$136,329

Medicare patients

1,886

Services billed

3,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EntrestoSacubitril/Valsartan	192	$290,720
JardianceEmpagliflozin	160	$189,520
EliquisApixaban	132	$171,867
FarxigaDapagliflozin Propanediol	33	$44,673
XareltoRivaroxaban	29	$38,573
Repatha SureclickEvolocumab	34	$25,722
Metoprolol Succinate	240	$4,271
Torsemide	68	$2,105
Losartan Potassium	144	$1,978
Carvedilol	192	$1,798
Atorvastatin Calcium	107	$1,747
Rosuvastatin Calcium	111	$1,649
Eplerenone	12	$1,584
Potassium Chloride	18	$970
Digoxin	39	$927

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Springfield

Sreekanth KaranamSpringfield$37K
Jay ChappellSpringfield$12K
Richard PadgettSpringfield$5K
Joseph ThouinSpringfield$5K
Ling JinSpringfield$4K
Sushan SweeneySpringfield$3K
Firas ZahrPortland$810K
Kathy GreweHood River$376K
Scott ChadderdonPortland$282K
Ahmad MasriPortland$227K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →